Bausch + Lomb Sets 2027 Start for Dry AMD Program
Bausch + Lomb announced an FDA meeting clarified the clinical path for BL1243 (tonabersat), an oral dry AMD candidate, and the company plans to initiate its clinical program in 2027.
Bausch + Lomb announced an FDA meeting clarified the clinical path for BL1243 (tonabersat), an oral dry AMD candidate, and the company plans to initiate its clinical program in 2027.